GYRE THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
GYRE$4.23-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Convertible Preferred Stock and Equity
(In thousands, except share amounts)
| Convertible Preferred Stock · Common Stock · AdditionalPaid-In · Statutory · Accumulated · Accumulated Other · Total Gyre Stockholders’ · Non-controlling · TotalEquity | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Reserve · Deficit · Comprehensive Loss · Equity · Interest | ||||||||||||||||||||
| Balances as of December 31, 2023 | 13,151 | $64,525 | 76,595,616 | $77 | $68,179 | $3,098 | $(85,538) | $(1,644) | $(15,828) | $29,777 | $13,949 | |||||||||
| Stock-based compensation expense | — | — | — | — | 831 | — | — | — | 831 | — | 831 | |||||||||
| Stock options exercised | — | — | 874,328 | 1 | 1,864 | — | — | — | 1,865 | — | 1,865 | |||||||||
| Convertible preferred stock conversion | (13,151) | (64,525) | 8,767,333 | 8 | 64,517 | — | — | — | 64,525 | — | 64,525 | |||||||||
| Issuance of Common Stock upon ATM program | — | — | 70,267 | — | 773 | — | — | — | 773 | — | 773 | |||||||||
| CVR Liability settlement | — | — | — | — | 30 | — | — | — | 30 | — | 30 | |||||||||
| Deferred Offering Costs Amortization | — | — | — | — | (9) | — | — | — | (9) | — | (9) | |||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | (953) | (953) | (507) | (1,460) | |||||||||
| Net income | — | — | — | — | — | — | 12,085 | — | 12,085 | 5,813 | 17,898 | |||||||||
| Balances as of December 31, 2024 | — | $— | 86,307,544 | $86 | $136,185 | $3,098 | $(73,453) | $(2,597) | $63,319 | $35,083 | $98,402 | |||||||||
| Stock-based compensation expense | — | — | — | — | 7,157 | — | — | — | 7,157 | — | 7,157 | |||||||||
| Stock options exercised | — | — | 2,396,174 | 2 | 2,354 | — | — | — | 2,356 | — | 2,356 | |||||||||
| Issuance of Common Stock upon ATM program | 54,734 | — | 509 | — | — | — | 509 | — | 509 | |||||||||||
| Issuance of Common Stock | — | — | 2,555,555 | 3 | 22,997 | — | — | — | 23,000 | — | 23,000 | |||||||||
| CVR Liability settlement | — | — | — | — | 25 | — | — | — | 25 | — | 25 | |||||||||
| Stock insurance cost | — | — | — | — | (1,676) | — | — | — | (1,676) | — | (1,676) | |||||||||
| Deferred Offering Costs amortization | — | — | — | — | (7) | — | — | — | (7) | — | (7) | |||||||||
| Capital injection in a subsidiary | — | — | — | — | 4,503 | — | — | — | 4,503 | (4,503) | — | |||||||||
| Foreign currency translation adjustment | — | — | — | — | — | — | — | 1,818 | 1,818 | 818 | 2,636 | |||||||||
| Net income | — | — | — | — | — | — | 5,027 | — | 5,027 | 4,853 | 9,880 | |||||||||
| Balances as of December 31, 2025 | — | $— | 91,314,007 | $91 | $172,047 | $3,098 | $(68,426) | $(779) | $106,031 | $36,251 | $142,282 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.